Ablynx says top drug shows benefit over rival

BRUSSELS (Reuters) – Belgian drug developer Ablynx said on Monday its top drug, arthritis treatment ozoralizumab, had shown a benefit over its biggest rival in the $24 billion market for this class of treatment.